A common cutaneous adverse reaction is the phenotypic switch from psoriasis to atopic eczema that occurs in up to 1%–12.1% of patients taking anti-TNF-α or anti-IL-17/IL-23 drugs.40 The gene discussed is IL17A; the disease is atopic eczema.